PAR2在MASLD进展和HCC发展中的作用
Pietro Guerra1, Patrizia Pontisso1, Andrea Martini2
1Department of Medicine, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.
International journal of molecular sciences
|August 14, 2025
概括
蛋白酶激活受体2 (PAR2) 与代谢功能障碍相关的脂肪性肝病 (MASLD) 进展和肝癌有关. 抑制PAR2在治疗MASLD及其并发症方面表现有前途.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 代谢功能障碍相关的脂肪性肝病 (MASLD) 是慢性肝病的主要原因,可能会发展为肝细胞癌 (HCC).
- 蛋白酶激活受体2 (PAR2),一种与G蛋白结合的受体,在MASLD和肝纤维化中被上调.
- PAR2激活通过SREBP1c激活,AMPK抑制和胰岛素耐药性,有助于代谢功能障碍.
研究的目的:
- 审查目前对PAR2在MASLD病变发生中的作用的理解.
- 探索PAR2作为MASLD和相关肝病的点的治疗潜力.
主要方法:
- 在肝病模型中研究PAR2表达和功能的研究文献综述.
- 在临床前的MASLD模型中对PAR2抑制的研究分析.
- 检查PAR2在炎症,纤维化和HCC发展中的参与.
主要成果:
- 在动物模型中,PAR2抑制有效地减少了MASLD的进展.
- PAR2阻塞通过抑制肝星细胞激活和关键介质来缓解晚期肝病的炎症和纤维化.
- PAR2通过增强瘤增殖,血管新生和免疫检查点抑制剂表达来促进HCC的发展.
结论:
- PAR2 是 MASLD 病原体和 HCC 的进展的重要贡献者.
- 向PAR2代表了管理MASLD和预防肝癌的有前途的治疗策略.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
1.1K
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
5.4K
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Mismatch Repair
5.2K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
5.2K
